Featured

Status

Health Topics

Any Category
Diseases
Neoplasms
Neoplasms by Histologic Type
Lymphoma
Clear Filters

Search Clinical Trials

34 Results
Recruiting
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Patients will give the investigators blood to make CD19 CD28 (with and without CD137) chimeric receptor-T cells in the laboratory. These cells will be grown and frozen. To make the …
Baylor Role: Lead Sponsor
Completed
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
The administration of allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person) that are made specific to fight EBV infection) in Children, Adolescents and Young Adults …
Baylor Role: Collaborator
Recruiting
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
Subjects (or their syngeneic donor) will give blood for investigators to make EBV-specific (GRALE) T cells in the lab. These cells will be grown and frozen for the subject. The …
Baylor Role: Lead Sponsor
Completed
Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies
The subject will need to have a variety of tests, exams, or procedures to find out if s/he can be on the study. The subject will also require placement of …
Baylor Role: Lead Sponsor
Completed
Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases
First, we will search our cell bank to see if there is a CTL line that is a match with the subject and his/her donor. This matching is done using …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL
The patient will give blood to make TAA-specific cytotoxic T cells in the lab. These cells will be grown and frozen. If the TAA-specific cytotoxic T cells can be made, …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Administration of Donor T Cells With the Caspase-9 Suicide Gene
If the patient is doing well after the stem cell transplant, and does not have severe GvHD, s/he will be eligible to receive the special "iCasp9" T cells from Day …
Baylor Role: Lead Sponsor
Withdrawn
Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
When the patient enrolls on this study, they will be assigned a dose of CD30 chimeric receptor-activated T cells. The dose level of cells that they will receive will not …
Baylor Role: Collaborator
Active, Not Recruiting
EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
The EBV CTLs will be made for specific patients. First blood will be collected from the patient and then the the CD30 chimeric-EBV CTLs will be created in the lab. …
Baylor Role: Lead Sponsor
Recruiting
Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL
To prepare the lymphoma, MM or CLL specific T cells investigators will take 240 ml (up to 16 tablespoonfuls)of blood from the patient. This would be drawn as 2 (two) …
Baylor Role: Lead Sponsor